Methadone Screen

If you take prescribed methadone, a positive urine screen is usually expected. It supports recent exposure, but it doesn't establish that you took every dose or the prescribed amount. An unexpected positive can reflect methadone exposure or a reaction with another substance.

Standard opiate screens mainly detect morphine and related compounds, including the products left after your body breaks down heroin or codeine. They generally miss methadone, which is why it needs a separate screen.

What the Screen Detects

This screen looks for methadone itself in a urine sample. It uses an immunoassay. This method relies on antibodies to recognize the drug and reports a positive or negative result. It is an established clinical screening method, though a positive is preliminary because other substances can sometimes react with the antibodies.

Your liver breaks methadone down into EDDP. This inactive breakdown product can also appear in urine. EDDP testing is separate from this parent-drug screen. Finding EDDP on a specific test provides evidence that your body processed methadone and can help investigate a result that doesn't fit your dosing history.

A urine result reflects drug excretion over a recent period. It doesn't measure the amount currently affecting your brain, your degree of opioid tolerance, or whether you're impaired. Even a confirmed positive cannot diagnose opioid use disorder on its own.

Breathing Risk

Methadone can slow or stop breathing. The risk is greater when treatment starts, after a dose increase, when opioid tolerance is low, and when it is combined with alcohol, benzodiazepines, or other opioids. Benzodiazepines include anxiety and sleep medicines such as alprazolam and diazepam. Methadone can accumulate during repeated dosing, so dangerous sedation may develop after doses that initially seemed well tolerated. Death rates are higher during the first four weeks of methadone treatment than later on.

Accidental ingestion can be fatal, especially in children. Research on blood collected after methadone-related deaths shows substantial overlap between concentrations found in fatal cases and those found during treatment. Those blood findings cannot be translated into a dangerous urine level. A urine screen cannot determine whether someone needs emergency treatment.

Heart Rhythm

Methadone can delay the heart's electrical recovery between beats and sometimes cause a dangerous rhythm called torsades de pointes. An ECG records the heart's electrical activity. Its QTc measurement helps assess that delay while accounting for heart rate. A 2026 review estimated that about 15% of people taking methadone develop a dose-related lengthening of the QTc.

Some other medicines increase methadone exposure or affect the heart's electrical recovery themselves. A large study of medical records found more diagnosed rhythm problems and deaths among people prescribed methadone than among those prescribed buprenorphine or naltrexone. Differences between the people receiving each treatment may explain part of the association. These were clinical outcomes, not predictions from urine screening results.

Long-Term Effects

A randomized trial comparing methadone with buprenorphine-naloxone found no difference in changes in liver enzymes over six months. Hepatitis infection and ongoing illicit drug use were associated with marked liver enzyme elevations. The study was reassuring about treatment safety, but it couldn't rule out every medication-related liver injury or establish safety over decades.

Sweating and constipation can persist during treatment. A 2026 review of medications for opioid use disorder reported sweating in about 15% and constipation in about 10% of people taking methadone. The same review reported testosterone deficiency in roughly 40% of men, and irregular periods in 47% and absent periods in about 8% of women. An older study of people still on methadone after at least three years also found that sweating and constipation could last. Human studies link methadone to sexual difficulties too, with more evidence in men than in women. A urine screen doesn't assess these effects.

When Results Can Be Misleading

• Cross-reacting medicines: diphenhydramine, doxylamine, quetiapine, vortioxetine, clomipramine, chlorpromazine, thioridazine, and verapamil have been linked to false-positive methadone results on some immunoassays. A large health-record analysis also found previously unrecognized cross-reactions on a particular methadone assay. How much this matters depends on the assay: in a 2026 real-world comparison, false-positive rates were about 30% on one widely used methadone immunoassay and about 5% on another.
• Urine acidity: when urine is less acidic, unchanged methadone can fall to a few percent of the dose, compared with roughly a third in more acidic urine. EDDP excretion is largely unaffected by urine acidity, so methadone may be undetected while EDDP remains detectable on a separate test.
• Dilution and timing: a dilute sample, a low dose, or collection too early or too long after exposure can produce a negative screen despite methadone use.
• Methadone without EDDP: confirmed methadone with little or no EDDP can raise concern that drug was added directly to a sample. Timing, metabolism, and the sensitivity of the separate tests also matter. This pattern alone doesn't establish tampering.
• Inferring the dose: studies measuring urine methadone and EDDP concentrations found wide variation even with observed dosing. This qualitative screen has no concentration to trend, and a concentration from a separate test cannot reliably reconstruct your dose.

Repeated Results During Treatment

Repeated screens can show whether methadone is detected consistently across collection dates. They still cannot establish that every dose was taken. Separate tests for EDDP and other drugs answer additional questions; their results aren't part of this methadone-only screen.

Research using broader urine drug testing in about 16,400 people receiving methadone found that fentanyl, methamphetamine, and cocaine positivity at the first collection increased between 2017 and 2021. Within the first year of follow-up, fentanyl and heroin positivity declined. These findings concern other drugs detected during treatment, not a change in the methadone screen itself.